Nutra Pharma Corp (NPHC) Non Operating Interest Expenses (2010 - 2026)

Nutra Pharma has disclosed Non Operating Interest Expenses across 17 years of filings, most recently posting $103922.0 for Q2 2026.

• In Q2 2026, Non Operating Interest Expenses rose 2.65% year-over-year to $103922.0; the TTM figure through Jun 2026 stood at $422020.0 (up 26.97% YoY), while the FY2025 annual figure was $417190.0, up 37.99% from the prior year.
• Non Operating Interest Expenses came in at $103922.0 for Q2 2026 at Nutra Pharma, up from $94360.0 in the prior quarter.
• In the past five years, Non Operating Interest Expenses ranged from a high of $195509.0 in Q2 2022 to a low of $61540.0 in Q4 2024.
• Average Non Operating Interest Expenses over 5 years is $115171.6, with a median of $97801.0 recorded in 2025.
• Year-over-year, Non Operating Interest Expenses surged 88.04% in 2022 and tumbled 60.43% in 2023.
• Over 5 years, Non Operating Interest Expenses stood at $194267.0 in 2022, then plunged by 60.43% to $76877.0 in 2023, then slipped by 19.95% to $61540.0 in 2024, then soared by 80.0% to $110773.0 in 2025, then slipped by 6.18% to $103922.0 in 2026.
• Per Business Quant data, the three most recent Non Operating Interest Expenses figures were $103922.0 in Q2 2026, $94360.0 in Q1 2026, and $110773.0 in Q4 2025.